The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer

Federico Rebaudi; Fabiana De Franco; Rayan Goda; Valentina Obino; Giorgio Vita; Camilla Baronti; Eleonora Iannone; Francesca Pitto; Barbara Massa; Daniela Fenoglio; Camilla Jandus; Francesca Poggio; Piero Fregatti; Ombretta Melaiu; Matteo Bozzo; Simona Candiani; Federica Papaccio; Marco Greppi; Silvia Pesce; Emanuela Marcenaro

doi:10.1016/j.ctrv.2024.102831

The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer

Cancer Treat Rev. 2024 Nov:130:102831. doi: 10.1016/j.ctrv.2024.102831. Epub 2024 Sep 24.

Authors

Federico Rebaudi¹, Fabiana De Franco¹, Rayan Goda¹, Valentina Obino¹, Giorgio Vita², Camilla Baronti¹, Eleonora Iannone³, Francesca Pitto⁴, Barbara Massa⁴, Daniela Fenoglio⁵, Camilla Jandus⁶, Francesca Poggio⁷, Piero Fregatti⁸, Ombretta Melaiu⁹, Matteo Bozzo¹⁰, Simona Candiani¹¹, Federica Papaccio¹², Marco Greppi¹³, Silvia Pesce¹⁴, Emanuela Marcenaro¹⁵

Affiliations

¹ Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy.
² Department of Internal Medicine (DIMI), University of Genoa, Genoa, Italy.
³ Breast Surgery Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
⁴ Department of Pathology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
⁵ Department of Internal Medicine (DIMI), University of Genoa, Genoa, Italy; Biotherapy Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
⁶ Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland; Geneva Center for Inflammation Research, Geneva, Switzerland.
⁷ Department of Medical Oncology, Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
⁸ Breast Surgery Clinic, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; Department of Integrated Surgical and Diagnostic Sciences (DISC), University of Genoa, Genoa, Italy.
⁹ Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, Italy.
¹⁰ Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy.
¹¹ Department of Earth, Environmental and Life Sciences (DISTAV), University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
¹² Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy.
¹³ Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy. Electronic address: [email protected].
¹⁴ Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy. Electronic address: [email protected].
¹⁵ Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy. Electronic address: [email protected].

PMID: 39342797
DOI: 10.1016/j.ctrv.2024.102831

Abstract

This review focuses on the immune checkpoint inhibitors (ICIs) in the context of breast cancer (BC) management. These innovative treatments, by targeting proteins expressed on both tumor and immune cells, aim to overcome tumor-induced immune suppression and reactivate the immune system. The potential of this approach is the subject of numerous clinical studies. Here, we explore the key studies and emerging therapies related to ICIs providing a detailed analysis of their specific and combined use in BC treatment.

Keywords: Breast cancer; Immune checkpoints; Immune checkpoints blockade; Immunotherapy; Targeted therapy.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms* / drug therapy
Breast Neoplasms* / immunology
Female
Humans
Immune Checkpoint Inhibitors* / therapeutic use

Substances

Immune Checkpoint Inhibitors